IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
20.04
+0.48 (2.45%)
At close: May 29, 2025, 4:00 PM
20.05
+0.01 (0.05%)
After-hours: May 29, 2025, 4:27 PM EDT
IDEAYA Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 130 | 84.38 | 157.02 | 68.63 | 92.05 | 72.04 | Upgrade
|
| Short-Term Investments | 562.51 | 591.94 | 368.1 | 296.2 | 154.72 | 211.55 | Upgrade
|
| Cash & Short-Term Investments | 692.51 | 676.32 | 525.11 | 364.83 | 246.77 | 283.59 | Upgrade
|
| Cash Growth | -0.90% | 28.79% | 43.93% | 47.84% | -12.98% | 186.58% | Upgrade
|
| Receivables | - | 0 | 0.02 | 0.21 | 1.1 | 1.88 | Upgrade
|
| Prepaid Expenses | 15.36 | 13.39 | 7.5 | 5.41 | 3.12 | 3.14 | Upgrade
|
| Total Current Assets | 707.87 | 689.71 | 532.63 | 370.45 | 251 | 288.61 | Upgrade
|
| Property, Plant & Equipment | 33.3 | 27.74 | 8.41 | 8.99 | 8.66 | 9.48 | Upgrade
|
| Long-Term Investments | 358.67 | 405.83 | 107.49 | 8.32 | 121.29 | - | Upgrade
|
| Other Long-Term Assets | 0.81 | 0.81 | 0.78 | 0.21 | 0.4 | 0.19 | Upgrade
|
| Total Assets | 1,101 | 1,124 | 649.32 | 387.97 | 381.35 | 298.27 | Upgrade
|
| Accounts Payable | 17.63 | 15.42 | 6.6 | 4.28 | 2.1 | 0.95 | Upgrade
|
| Accrued Expenses | 32.91 | 30.35 | 18.76 | 17 | 12.32 | 8.52 | Upgrade
|
| Current Portion of Leases | 0.31 | 0.3 | 1.75 | 1.87 | 1.7 | 1.54 | Upgrade
|
| Current Unearned Revenue | - | - | - | 8.57 | 29.04 | 27.61 | Upgrade
|
| Other Current Liabilities | - | - | - | - | - | 0.02 | Upgrade
|
| Total Current Liabilities | 50.85 | 46.07 | 27.1 | 31.72 | 45.16 | 38.64 | Upgrade
|
| Long-Term Leases | 25.66 | 18.87 | 1.13 | 1.61 | 3.48 | 5.18 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 5.19 | 31.19 | 56.16 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 0.01 | Upgrade
|
| Total Liabilities | 76.51 | 64.94 | 28.23 | 38.51 | 79.83 | 100 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,718 | 1,681 | 968.89 | 587.72 | 478.97 | 325.25 | Upgrade
|
| Retained Earnings | -695.02 | -622.84 | -348.36 | -235.4 | -176.75 | -126.99 | Upgrade
|
| Comprehensive Income & Other | 1.59 | 0.81 | 0.56 | -2.87 | -0.71 | 0.01 | Upgrade
|
| Total Common Equity | 1,024 | 1,059 | 621.09 | 349.46 | 301.51 | 198.27 | Upgrade
|
| Shareholders' Equity | 1,024 | 1,059 | 621.09 | 349.46 | 301.51 | 198.27 | Upgrade
|
| Total Liabilities & Equity | 1,101 | 1,124 | 649.32 | 387.97 | 381.35 | 298.27 | Upgrade
|
| Total Debt | 25.97 | 19.17 | 2.87 | 3.48 | 5.18 | 6.72 | Upgrade
|
| Net Cash (Debt) | 1,025 | 1,063 | 629.73 | 369.66 | 362.88 | 276.86 | Upgrade
|
| Net Cash Growth | 9.18% | 68.80% | 70.35% | 1.87% | 31.07% | 195.45% | Upgrade
|
| Net Cash Per Share | 12.06 | 13.01 | 10.95 | 8.92 | 10.29 | 11.20 | Upgrade
|
| Filing Date Shares Outstanding | 87.58 | 87.54 | 74.56 | 48.39 | 38.63 | 32.25 | Upgrade
|
| Total Common Shares Outstanding | 87.57 | 86.5 | 65.04 | 48.19 | 38.53 | 29.52 | Upgrade
|
| Working Capital | 657.03 | 643.64 | 505.53 | 338.74 | 205.84 | 249.97 | Upgrade
|
| Book Value Per Share | 11.70 | 12.24 | 9.55 | 7.25 | 7.82 | 6.72 | Upgrade
|
| Tangible Book Value | 1,024 | 1,059 | 621.09 | 349.46 | 301.51 | 198.27 | Upgrade
|
| Tangible Book Value Per Share | 11.70 | 12.24 | 9.55 | 7.25 | 7.82 | 6.72 | Upgrade
|
| Machinery | 16 | 15.53 | 12.22 | 10.51 | 7.02 | 5.33 | Upgrade
|
| Leasehold Improvements | 4.94 | 4.91 | 3.32 | 3.32 | 3.13 | 2.72 | Upgrade
|
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.